Back to results
US 2023/0407310 A1Published application
Treatment of optic atrophy
AssigneePYC Therapeutics Limited
InventorsFred Chen, Ianthe Pitout, Janya Grainok, Sasiwimon Utama, Kim Rice
Life of this patent
Estimating the term…
Abstract
An isolated or purified antisense oligomer for modulating mRNA translation of the OPAL gene transcript or part thereof which has a modified backbone structure and sequences with at least 75% sequence identity to the isolated or purified antisense oligomer.
Claims23
An isolated or purified antisense oligomer for modulating mRNA translation of the OPA1 gene transcript or part thereof which has a modified backbone structure and sequences with at least 75% sequence identity to the isolated or purified antisense oligomer.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.